GBA1 and Parkinson disease: Unfortunately, substrate reduction therapy, which blocks the formation of pathological substrates via GluCer synthase inhibitors, does not alter the progression of GBA1-PD [12], and it fails to target GCase dysfunction upstream of the lipid pathology.